Prosecution Insights
Last updated: October 02, 2026

Examiner: DUNSTON, JENNIFER ANN

Tech Center 1600 • Art Units: 1600 1614 1635 1636 1637 1699

This examiner grants 48% of resolved cases

Analysis

Jennifer Ann Dunston is an examiner in Tech Center 1600, specifically Art Unit 1600. She has managed 730 resolved cases. This extensive experience in the biotechnology and organic chemistry fields provides a reliable basis for analyzing her prosecution tendencies. Her high volume of resolutions indicates a seasoned examiner who is well-versed in the specific challenges of Tech Center 1600.

The examiner maintains an allowance rate of 47.5 percent. A particularly striking data point is the interview lift of 50.5 percent. This is an exceptionally high lift, suggesting that interviews are incredibly effective at overcoming hurdles in her examination process. For practitioners, this 50.5 percent increase in allowance probability after an interview represents a critical tactical recommendation. Direct communication appears to be the primary driver for moving applications toward a grant in her art unit.

The median days to allowance for her cases is 1437. This duration is relatively long, reflecting the typical complexities found in biotechnology prosecution. When combined with the 47.5 percent allowance rate, the 1437-day median suggests that while the path to allowance is challenging, it is significantly aided by the use of interviews. Applicants should budget for a longer prosecution timeline while prioritizing early and frequent examiner contact to leverage the 50.5 percent lift.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

47.5%
Allow Rate
-12.5% vs TC avg
742
Total Applications
+50.5%
Interview Lift
1437
Avg Prosecution Days
Based on 730 resolved cases, 2023–2026

Rejection Statute Breakdown

9.6%
§101 Eligibility
15.4%
§102 Novelty
27.7%
§103 Obviousness
34.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17269968 TREATMENT OF FLAVIVIRUS INFECTIONS IN HUMANS USING MUS MUSCULUS RESISTANT 2'-5' OLIGOADENYLATE SYNTHETASE 1B Final Rejection Georgia Tech Research Corporation
18282676 POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA Non-Final OA ModernaTX, Inc.
17606605 COMPOSITIONALLY DEFINED PLASMID DNA/POLYCATION NANOPARTICLES AND METHODS FOR MAKING THE SAME Final Rejection The Johns Hopkins University

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month